Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

G. Comi; F. Patti; M.A. Rocca; F.C. Mattioli; M.P. Amato; P. Gallo; D. Centonze; C. Pozzilli; F. Saccà; F.T. Bergh; M. Bartezaghi; R. Turrini; M. Filippi; For the Golden Study Group; F. Patti; C.G. Chisari; G.A. Marfia; D. Centonze; V.B. Morra; R. Capra; C. Pozzilli; V. Bianchi; A. Ghezzi; M. Roscio; G. Comi; F. Sangalli; E. Pietrolongo; A. Francia; M.C. Danni; U. Nocentini; P. Bramanti; G. Tedeschi; D. Maimone; L.M.E. Grimaldi; E.A. Scarpini; A. Uccelli; M.P. Amato; M. Rottoli; S. Ruggieri; M. Trojano; R. Bergamaschi; F.T. Bergh; M. Buttmann; P. Rieckmann; A. Safavi

doi:10.1007/s00415-017-8642-5

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

G. Comi, F. Patti, M.A. Rocca, F.C. Mattioli, M.P. Amato, P. Gallo, D. Centonze, C. Pozzilli, F. Saccà, F.T. Bergh, M. Bartezaghi, R. Turrini, M. Filippi, For the Golden Study Group, F. Patti, C.G. Chisari, G.A. Marfia, D. Centonze, V.B. Morra, R. CapraC. Pozzilli, V. Bianchi, A. Ghezzi, M. Roscio, G. Comi, F. Sangalli, E. Pietrolongo, A. Francia, M.C. Danni, U. Nocentini, P. Bramanti, G. Tedeschi, D. Maimone, L.M.E. Grimaldi, E.A. Scarpini, A. Uccelli, M.P. Amato, M. Rottoli, S. Ruggieri, M. Trojano, R. Bergamaschi, F.T. Bergh, M. Buttmann, P. Rieckmann, A. Safavi

Research output: Contribution to journal › Article

Original language	English
Pages (from-to)	2436-2449
Number of pages	14
Journal	Journal of Neurology
Volume	264
Issue number	12
DOIs	https://doi.org/10.1007/s00415-017-8642-5
Publication status	Published - 2017

Keywords

azathioprine
beta1a interferon
fingolimod
gadolinium
glatiramer
interferon beta serine
mitoxantrone
natalizumab, adult
Article
brain size
clinical feature
clinical outcome
cognition
connective tissue disease
contrast enhancement
controlled study
Delis-Kaplan executive function system
disease course
disease severity
drug efficacy
drug safety
drug tolerability
executive function test
Expanded Disability Status Scale
eye disease
female
gastrointestinal disease
hematologic disease
human
infection
infestation
injection site reaction
injury
intoxication
kidney disease
lymphatic system disease
major clinical study
male
mediastinum disease
mental disease
metabolic disorder
Montgomery Asberg Depression Rating Scale
multicenter study
multiple sclerosis
musculoskeletal disease
neuroimaging
neurologic disease
nuclear magnetic resonance imaging
nutritional disorder
open study
paced auditory serial addition test
pilot study
priority journal
randomized controlled trial
Rao Brief Repeatable Battery
recurrence risk
respiratory tract disease
risk assessment
risk benefit analysis
side effect
skin disease
symbol digit modalities test
thorax disease
treatment duration
urinary tract disease
vascular disease

Access to Document

10.1007/s00415-017-8642-5

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85031941975&doi=10.1007%2fs00415-017-8642-5&partnerID=40&md5=75ecd928ba8e8782d3bac04afc99b534

Cite this

Comi, G., Patti, F., Rocca, M. A., Mattioli, F. C., Amato, M. P., Gallo, P., Centonze, D., Pozzilli, C., Saccà, F., Bergh, F. T., Bartezaghi, M., Turrini, R., Filippi, M., Group, F. T. G. S., Patti, F., Chisari, C. G., Marfia, G. A., Centonze, D., Morra, V. B., ... Safavi, A. (2017). Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology, 264(12), 2436-2449. https://doi.org/10.1007/s00415-017-8642-5

Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). / Comi, G.; Patti, F.; Rocca, M.A.; Mattioli, F.C.; Amato, M.P.; Gallo, P.; Centonze, D.; Pozzilli, C.; Saccà, F.; Bergh, F.T.; Bartezaghi, M.; Turrini, R.; Filippi, M.; Group, For the Golden Study; Patti, F.; Chisari, C.G.; Marfia, G.A.; Centonze, D.; Morra, V.B.; Capra, R.; Pozzilli, C.; Bianchi, V.; Ghezzi, A.; Roscio, M.; Comi, G.; Sangalli, F.; Pietrolongo, E.; Francia, A.; Danni, M.C.; Nocentini, U.; Bramanti, P.; Tedeschi, G.; Maimone, D.; Grimaldi, L.M.E.; Scarpini, E.A.; Uccelli, A.; Amato, M.P.; Rottoli, M.; Ruggieri, S.; Trojano, M.; Bergamaschi, R.; Bergh, F.T.; Buttmann, M.; Rieckmann, P.; Safavi, A.

In: Journal of Neurology, Vol. 264, No. 12, 2017, p. 2436-2449.

Research output: Contribution to journal › Article

Comi, G, Patti, F, Rocca, MA, Mattioli, FC, Amato, MP, Gallo, P, Centonze, D, Pozzilli, C, Saccà, F, Bergh, FT, Bartezaghi, M, Turrini, R, Filippi, M, Group, FTGS, Patti, F, Chisari, CG, Marfia, GA, Centonze, D, Morra, VB, Capra, R, Pozzilli, C, Bianchi, V, Ghezzi, A, Roscio, M, Comi, G, Sangalli, F, Pietrolongo, E, Francia, A, Danni, MC, Nocentini, U , Bramanti, P, Tedeschi, G, Maimone, D, Grimaldi, LME, Scarpini, EA , Uccelli, A , Amato, MP, Rottoli, M, Ruggieri, S, Trojano, M, Bergamaschi, R, Bergh, FT, Buttmann, M, Rieckmann, P & Safavi, A 2017, 'Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)', Journal of Neurology, vol. 264, no. 12, pp. 2436-2449. https://doi.org/10.1007/s00415-017-8642-5

Comi G, Patti F, Rocca MA, Mattioli FC, Amato MP, Gallo P et al. Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). Journal of Neurology. 2017;264(12):2436-2449. https://doi.org/10.1007/s00415-017-8642-5

Comi, G. ; Patti, F. ; Rocca, M.A. ; Mattioli, F.C. ; Amato, M.P. ; Gallo, P. ; Centonze, D. ; Pozzilli, C. ; Saccà, F. ; Bergh, F.T. ; Bartezaghi, M. ; Turrini, R. ; Filippi, M. ; Group, For the Golden Study ; Patti, F. ; Chisari, C.G. ; Marfia, G.A. ; Centonze, D. ; Morra, V.B. ; Capra, R. ; Pozzilli, C. ; Bianchi, V. ; Ghezzi, A. ; Roscio, M. ; Comi, G. ; Sangalli, F. ; Pietrolongo, E. ; Francia, A. ; Danni, M.C. ; Nocentini, U. ; Bramanti, P. ; Tedeschi, G. ; Maimone, D. ; Grimaldi, L.M.E. ; Scarpini, E.A. ; Uccelli, A. ; Amato, M.P. ; Rottoli, M. ; Ruggieri, S. ; Trojano, M. ; Bergamaschi, R. ; Bergh, F.T. ; Buttmann, M. ; Rieckmann, P. ; Safavi, A. / Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study). In: Journal of Neurology. 2017 ; Vol. 264, No. 12. pp. 2436-2449.

@article{958b1ea00be043e09282098e76720575,

title = "Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)",

keywords = "azathioprine, beta1a interferon, fingolimod, gadolinium, glatiramer, interferon beta serine, mitoxantrone, natalizumab, adult, Article, brain size, clinical feature, clinical outcome, cognition, connective tissue disease, contrast enhancement, controlled study, Delis-Kaplan executive function system, disease course, disease severity, drug efficacy, drug safety, drug tolerability, executive function test, Expanded Disability Status Scale, eye disease, female, gastrointestinal disease, hematologic disease, human, infection, infestation, injection site reaction, injury, intoxication, kidney disease, lymphatic system disease, major clinical study, male, mediastinum disease, mental disease, metabolic disorder, Montgomery Asberg Depression Rating Scale, multicenter study, multiple sclerosis, musculoskeletal disease, neuroimaging, neurologic disease, nuclear magnetic resonance imaging, nutritional disorder, open study, paced auditory serial addition test, pilot study, priority journal, randomized controlled trial, Rao Brief Repeatable Battery, recurrence risk, respiratory tract disease, risk assessment, risk benefit analysis, side effect, skin disease, symbol digit modalities test, thorax disease, treatment duration, urinary tract disease, vascular disease",

author = "G. Comi and F. Patti and M.A. Rocca and F.C. Mattioli and M.P. Amato and P. Gallo and D. Centonze and C. Pozzilli and F. Sacc{\`a} and F.T. Bergh and M. Bartezaghi and R. Turrini and M. Filippi and Group, {For the Golden Study} and F. Patti and C.G. Chisari and G.A. Marfia and D. Centonze and V.B. Morra and R. Capra and C. Pozzilli and V. Bianchi and A. Ghezzi and M. Roscio and G. Comi and F. Sangalli and E. Pietrolongo and A. Francia and M.C. Danni and U. Nocentini and P. Bramanti and G. Tedeschi and D. Maimone and L.M.E. Grimaldi and E.A. Scarpini and A. Uccelli and M.P. Amato and M. Rottoli and S. Ruggieri and M. Trojano and R. Bergamaschi and F.T. Bergh and M. Buttmann and P. Rieckmann and A. Safavi",

year = "2017",

doi = "10.1007/s00415-017-8642-5",

language = "English",

volume = "264",

pages = "2436--2449",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

number = "12",

}

TY - JOUR

T1 - Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

AU - Comi, G.

AU - Patti, F.

AU - Rocca, M.A.

AU - Mattioli, F.C.

AU - Amato, M.P.

AU - Gallo, P.

AU - Centonze, D.

AU - Pozzilli, C.

AU - Saccà, F.

AU - Bergh, F.T.

AU - Bartezaghi, M.

AU - Turrini, R.

AU - Filippi, M.

AU - Group, For the Golden Study

AU - Patti, F.

AU - Chisari, C.G.

AU - Marfia, G.A.

AU - Centonze, D.

AU - Morra, V.B.

AU - Capra, R.

AU - Pozzilli, C.

AU - Bianchi, V.

AU - Ghezzi, A.

AU - Roscio, M.

AU - Comi, G.

AU - Sangalli, F.

AU - Pietrolongo, E.

AU - Francia, A.

AU - Danni, M.C.

AU - Nocentini, U.

AU - Bramanti, P.

AU - Tedeschi, G.

AU - Maimone, D.

AU - Grimaldi, L.M.E.

AU - Scarpini, E.A.

AU - Uccelli, A.

AU - Amato, M.P.

AU - Rottoli, M.

AU - Ruggieri, S.

AU - Trojano, M.

AU - Bergamaschi, R.

AU - Bergh, F.T.

AU - Buttmann, M.

AU - Rieckmann, P.

AU - Safavi, A.

PY - 2017

Y1 - 2017

KW - azathioprine

KW - beta1a interferon

KW - fingolimod

KW - gadolinium

KW - glatiramer

KW - interferon beta serine

KW - mitoxantrone

KW - natalizumab, adult

KW - Article

KW - brain size

KW - clinical feature

KW - clinical outcome

KW - cognition

KW - connective tissue disease

KW - contrast enhancement

KW - controlled study

KW - Delis-Kaplan executive function system

KW - disease course

KW - disease severity

KW - drug efficacy

KW - drug safety

KW - drug tolerability

KW - executive function test

KW - Expanded Disability Status Scale

KW - eye disease

KW - female

KW - gastrointestinal disease

KW - hematologic disease

KW - human

KW - infection

KW - infestation

KW - injection site reaction

KW - injury

KW - intoxication

KW - kidney disease

KW - lymphatic system disease

KW - major clinical study

KW - male

KW - mediastinum disease

KW - mental disease

KW - metabolic disorder

KW - Montgomery Asberg Depression Rating Scale

KW - multicenter study

KW - multiple sclerosis

KW - musculoskeletal disease

KW - neuroimaging

KW - neurologic disease

KW - nuclear magnetic resonance imaging

KW - nutritional disorder

KW - open study

KW - paced auditory serial addition test

KW - pilot study

KW - priority journal

KW - randomized controlled trial

KW - Rao Brief Repeatable Battery

KW - recurrence risk

KW - respiratory tract disease

KW - risk assessment

KW - risk benefit analysis

KW - side effect

KW - skin disease

KW - symbol digit modalities test

KW - thorax disease

KW - treatment duration

KW - urinary tract disease

KW - vascular disease

U2 - 10.1007/s00415-017-8642-5

DO - 10.1007/s00415-017-8642-5

M3 - Article

VL - 264

SP - 2436

EP - 2449

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 12

ER -